87 related articles for article (PubMed ID: 37410453)
1. Recent advances in anaplastic thyroid cancer management.
Hamidi S; Maniakas A
Curr Opin Endocrinol Diabetes Obes; 2023 Oct; 30(5):259-264. PubMed ID: 37410453
[TBL] [Abstract][Full Text] [Related]
2. Advances in the management of anaplastic thyroid carcinoma: transforming a life-threatening condition into a potentially treatable disease.
Califano I; Smulever A; Jerkovich F; Pitoia F
Rev Endocr Metab Disord; 2024 Feb; 25(1):123-147. PubMed ID: 37648897
[TBL] [Abstract][Full Text] [Related]
3. Combination
Gunda V; Ghosh C; Hu J; Zhang L; Zhang YQ; Shen M; Kebebew E
Thyroid; 2023 Oct; 33(10):1201-1214. PubMed ID: 37675898
[No Abstract] [Full Text] [Related]
4. Anaplastic thyroid cancer:Improved understanding of what remains a deadly disease.
Cleere EF; Prunty S; O'Neill JP
Surgeon; 2024 Feb; 22(1):e48-e53. PubMed ID: 37866980
[TBL] [Abstract][Full Text] [Related]
5. [Molecular diagnostics enable targeted therapies for anaplastic and poorly differentiated thyroid cancer].
Altena R; Nilsson M; Bergman V; Dahlberg J; Christofer Juhlin C; Zedenius J
Lakartidningen; 2024 Feb; 121():. PubMed ID: 38712675
[TBL] [Abstract][Full Text] [Related]
6. Mutation-based, short-term "neoadjuvant" treatment allows resectability in stage IVB and C anaplastic thyroid cancer.
Maurer E; Eilsberger F; Wächter S; Riera Knorrenschild J; Pehl A; Holzer K; Neubauer A; Luster M; Bartsch DK
Eur Arch Otorhinolaryngol; 2023 Mar; 280(3):1509-1518. PubMed ID: 36637521
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of MEK Signaling Attenuates Cancer Stem Cell Activity in Anaplastic Thyroid Cancer.
Kimura T; Doolittle WKL; Kruhlak M; Zhao L; Hwang E; Zhu X; Tang B; Wolcott KM; Cheng SY
Thyroid; 2024 Apr; 34(4):484-495. PubMed ID: 38115586
[No Abstract] [Full Text] [Related]
8. Progress in Treating Advanced Thyroid Cancers in the Era of Targeted Therapy.
Lubitz CC; Sadow PM; Daniels GH; Wirth LJ
Thyroid; 2021 Oct; 31(10):1451-1462. PubMed ID: 33860688
[No Abstract] [Full Text] [Related]
9. [Personalized approach to anaplastic thyroid carcinoma].
Wächter S; Bartsch DK; Maurer E
Chirurgie (Heidelb); 2024 Mar; 95(3):192-199. PubMed ID: 37973622
[TBL] [Abstract][Full Text] [Related]
10. Anaplastic thyroid cancer spheroids as preclinical models to test therapeutics.
Hu J; Liu K; Ghosh C; Khaket TP; Shih H; Kebebew E
J Exp Clin Cancer Res; 2024 Mar; 43(1):85. PubMed ID: 38500204
[TBL] [Abstract][Full Text] [Related]
11. Integrative Multi-omics Analysis Reveals Different Metabolic Phenotypes Based on Molecular Characteristics in Thyroid Cancer.
Kim YH; Yoon SJ; Kim M; Kim HH; Song YS; Jung JW; Han D; Cho SW; Kwon SW; Park YJ
Clin Cancer Res; 2024 Feb; 30(4):883-894. PubMed ID: 38088902
[TBL] [Abstract][Full Text] [Related]
12. 2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer.
Bible KC; Kebebew E; Brierley J; Brito JP; Cabanillas ME; Clark TJ; Di Cristofano A; Foote R; Giordano T; Kasperbauer J; Newbold K; Nikiforov YE; Randolph G; Rosenthal MS; Sawka AM; Shah M; Shaha A; Smallridge R; Wong-Clark CK
Thyroid; 2021 Mar; 31(3):337-386. PubMed ID: 33728999
[No Abstract] [Full Text] [Related]
13. New Insights into Immune Cells and Immunotherapy for Thyroid Cancer.
Tao Y; Li P; Feng C; Cao Y
Immunol Invest; 2023 Nov; 52(8):1039-1064. PubMed ID: 37846977
[TBL] [Abstract][Full Text] [Related]
14. BRAFV600E restructures cellular lactylation to promote anaplastic thyroid cancer proliferation.
Wang X; Ying T; Yuan J; Wang Y; Su X; Chen S; Zhao Y; Zhao Y; Sheng J; Teng L; Luo C; Wang W
Endocr Relat Cancer; 2023 Aug; 30(8):. PubMed ID: 37184950
[TBL] [Abstract][Full Text] [Related]
15. Prolonged survival of anaplastic thyroid carcinoma is associated with resectability, low tumor-infiltrating neutrophils/myeloid-derived suppressor cells, and low peripheral neutrophil-to-lymphocyte ratio.
Xu B; Zhang L; Setoodeh R; Mohanty AS; Landa I; Balzer B; Tiedje V; Ganly I; Dogan S; Fagin JA; Ghossein R
Endocrine; 2022 Jun; 76(3):612-619. PubMed ID: 35149932
[TBL] [Abstract][Full Text] [Related]
16. Novel approaches in anaplastic thyroid cancer therapy.
Hsu KT; Yu XM; Audhya AW; Jaume JC; Lloyd RV; Miyamoto S; Prolla TA; Chen H
Oncologist; 2014 Nov; 19(11):1148-55. PubMed ID: 25260367
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of BRAF/MEK inhibitors in BRAFV600E-mutated anaplastic thyroid cancer: a systematic review and meta-analysis.
Priantti JN; Rodrigues NMV; de Moraes FCA; da Costa AG; Jezini DL; Heckmann MIO
Endocrine; 2024 May; ():. PubMed ID: 38709445
[TBL] [Abstract][Full Text] [Related]
18. Omics sciences and precision medicine in thyroid cancer.
Dhuli K; Medori MC; Donato K; Donato K; Maltese PE; Tanzi B; Tezzele S; Mareso C; Miertus J; Generali D; Donofrio CA; Cominetti M; Fioravanti A; Riccio L; Beccari T; Ceccarini MR; Stuppia L; Stuppia L; Gatta V; Cristoni S; Cecchin S; Marceddu G; Bertelli M
Clin Ter; 2023; 174(Suppl 2(6)):11-20. PubMed ID: 37994744
[TBL] [Abstract][Full Text] [Related]
19. Anaplastic thyroid cancer: Pathogenesis, prognostic factors and genetic landscape (Review).
Alhejaily AG; Alhuzim O; Alwelaie Y
Mol Clin Oncol; 2023 Dec; 19(6):99. PubMed ID: 38022847
[TBL] [Abstract][Full Text] [Related]
20. A Multicentre Retrospective Study of Anaplastic Thyroid Cancer in the Era of Targeted Therapy in a Public Health Care System: Canada's Experience.
Gupta MK; Misariu AM; Saydy N; Nichols AC; Laxague F; Eskander A; Li H; Weisbrod N; Pasternak JD; Golbon B; Jin E; van Uum SHM; Brassard M; Lévesque F; Sadeghi N; Subramaniam T; Mlynarek AM; Morand GB; Fortier PH; Fradet L; Ghaznavi S; Chandarana SP; Prisman E; Ayad T; Christopoulos A; Davies JC; Rajaraman M; Corsten M; Rajaraman K; Maniakas A
Thyroid; 2023 Nov; 33(11):1374-1377. PubMed ID: 37725592
[No Abstract] [Full Text] [Related]
[Next] [New Search]
